Features of management of fungal infections of the skin and its appendages in the risk groups

Close metadata

Recommended articles:

Lasers and photodynamic therapy in treatment of onychomycoses. Russian Journal of Clinical Dermatology and Venereology. 2024;(3):258-263

Clinical and Laboratory Features of Nail Lesions in Patients Who Used External Antifungal Drugs by Themselves. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):724-729

Fatal case of rhinocerebral mucormycosis on the background of type II diabetes mellitus. Russian Journal of Archive of Pathology. 2024;(3):52-58

Prevalence of diabetic retinopathy assessed using two-field mydriatic fundus photography. Russian Annals of Ophthalmology. 2024;(4):60-67

Objective: To evaluate the efficacy and tolerability of the treatment of fungal infections of the skin and nail plates with naftifine in patients in risk groups. Material and methods. Prospective clinical study (2011-2013). Results. 78 records of patients with onychomycosis (51 men and 27 women aged 21-78 years) were selected. Cutaneous fungal lesions of the torso, feet, and large folds were diagnosed in 35 (44.9% ) of them. Twenty-nine (82.8 %) of 35 patients recovered from fungal infections of the due to applying 1% Exoderil lotion. Topical application of 1% Exoderil solution and following the sanitary measures allowed 45 (57.7%) patients to recover from onychomycosis; the nail plate improved in 29 (37.2 %) patients; no effect was observed in 4 (5.1%) of 78 patients. Adverse effects on the skin due to the use of 1% Exoderil lotion were either mild or moderate (burning, dryness, erythema, itching and local irritation) and were extremely rare. Conclusions. Naftifine demonstrated high activity against many clinically important fungal pathogens with good tolerability.

Keywords:

onychomycosis

mycoses

risk groups

naftifine

Authors:

Burova S.A.

Tsentr glubokikh mikozov;
GKB #81;
Moskovskiĭ nauchno-prakticheskiĭ tsentr dermatovenerologii i kosmetologii Departamenta zdravookhraneniia Moskvy

List of references:

Sergeev A.Yu., Ivanov O.L., Sergeev Yu.V., Vakhlakov A.N., Sedova T.N., Dudnik V.S. Issledovanie sovremennoy epidemiologii onikhomikoza. [The study of current epidemiology of onychomycosis] Vestn dermatol i venerol 2002; 3: 31-35 (In Russian).
Tsykin A.A., Lomonosov K.M. Onikhomikoz: etiologiya, diagnostika, klinika i lechenie. [Onychomycosis: etiology, diagnosis, clinical features and treatment] Ros med zhurn 2007; 15(19): 371-376 (In Russian).
Burova S.A. Lechenie onikhomikoza u bol'nykh sakharnym diabetom ili s narushennoy tolerantnost'yu k glyukoze. [Treatment of onychomycosis in patients with diabetes or impaired glucose tolerance] Vestn dermatol 2005; 6: 55-57 (In Russian).
Sergeev A.Yu., Sergeev Yu.V. Onikhomikozy i sovremennaya dermatologiya: mediko-sotsial'nye aspekty. V sb.: Uspekhi meditsinskoy mikologii. [Onychomycosis and modern dermatology: medical and social aspects. In: Advance of Medical Mycology] Moscow 2007; 10: 17 (In Russian).
Pierard G.E., Pierard-Franchimont C. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses 2005; 48(5): 339-342.
Mendez-Tovar L.J. Pathogenesis of dermatophytosis and tinea versicolor. Clin Dermatol 2010; 28(2): 185-189.
Scher R.K., Tavakkol A., Sigurgeirsson B., Hay R.J., Joseph W.S., Tosti A., Fleckman P., Ghannoum M., Armstrong D.G., Markinson B.C., Elewski B.E. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007; 56(6): 939-944.
Monk J.P., Brogden R.N. Naftifine. A. review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 1991; 42: 659-672.
Gosudarstvennyy reestr lekarstvennykh sredstv. [State register of medicines] http://grls.rosminzdrav.ru/. Accessed December 25, 2013 (In Russian).
J Am Acad Dermatol 2012; 66:AB119. P5234.
Rosen T., Schell B.J., Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997; 36: 788-792.
Solomon D.A., Lee W.L., Geen S.C. et al. Modification of neutrophil functions by naftifine. Br J Dermatol 1993; 128: 393-398.
Sergeev Yu.V. et al. Ekzoderil v terapii opportunisticheskoy infektsii kozhi i infektsionno-vospalitel'nykh dermatozov. [Exoderil in the therapy of opportunistic infections of the skin and infectious and inflammatory dermatoses] Ros zhurn kozhn i ven bol 2004; 6: 36-41 (In Russian).
Evans E.G., James I.G., Seaman R.A., Richardson M.D. Does naftifine have anti-inflammatory properties- A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infections of the skin. Br J Dermatol 1993; 129(4): 437-442.
Sergeev A.Yu., Sergeev Yu.V., Sergeev V.Yu. Novye kontseptsii patogeneza diagnostiki i terapii onikhomikozov. [New concepts of the pathogenesis and diagnosis of onychomycosis therapy] Immunologiya. Allergologiya. Infektologiya 2007; 3: 8-10 (In Russian).
Effendy I., Friederich H.C. Double-blind, randomized comparative study of naftifine solution (once daily) and clotrimazole solution (twice daily) in the treatment of dermatomycoses. Mykosen 1987; 30(Suppl 1): 104-111.
Millikan L.E., Galen W.K., Gewirtzman G.B. et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 1988; 18: 52-56.
Naftin (naftifine hydrochloride) 1% cream product information. Merz Pharmaceuticals physicians' desk reference. Vol. 57. Montvale (NJ): Thomson PDR; 2003., p. 2132-2133.
Naftifine treatment for dermatophytosis: multicenter clinical investigations in Turkey. Turkish Multicenter Dermatophytosis Study Group. Int J Dermatol 1992; 31(4): 247-248.
Sergeev Yu.V., Mokina E.V., Chernyavskaya M.G., Buchinskiy O.I., Savchenko N.V. Problemy i perspektivy terapii i profilaktiki mikozov stop i onikhomikozov. [Problems and prospects of treatment and prevention of foot mycoses and onychomycosis] RMZh, vol. 12, 2004; 18; 3-9 (In Russian).

Close metadata